用不同的二进制终点进行两阶段自适应无设计的统计推理
Ryota Ishii1, Kenichi Takahashi2, Kazushi Maruo1
1Department of Biostatistics, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Statistics in medicine
|March 6, 2025
概括
本研究引入了新的统计方法,条件平均调整估计器 (CMAE) 和均最小方差条件无偏估计器 (UMVCUE),以减少适应无试验设计中的偏差. 这些方法改善了药物开发中的治疗效果估计.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 制药发展 制药发展
背景情况:
- 适应性无设计整合了II期和III期试验,以实现高效的药物开发.
- 这些设计包括在第一阶段选择治疗方法,并在第二阶段比较疗效.
- 使用最大概率估计器 (MLE) 的现有方法在治疗效果估计中显示上升偏差.
研究的目的:
- 提出和评估新的统计估计器,CMAE和UMVCUE,以解决两阶段适应无设计中的偏差.
- 为了比较这些新的估计器与MLE的性能,结合精确和中期p测试.
- 在这种试验设计环境中提供最佳统计推断的建议.
主要方法:
- 开发了条件平均调整估计器 (CMAE) 和统一最小方差条件无偏估计器 (UMVCUE).
- 使用克洛珀-皮尔森方法构建的置信区间,用于精确和中等p测试.
- 进行模拟研究来比较六种推断方法 (三个估计器×两个测试).
主要成果:
- 最大概率估计器 (MLE) 在治疗效果估计中表现出显著的上升偏差.
- CMAE和UMVCUE大大降低了这种偏差.
- 中期p测试保持了接近名义水平的I型错误率,而精确测试则是保守的.
结论:
- 在自适应无试验设计中,CMAE和UMVCUE有效地减轻了偏差.
- 与精确测试相比,中期p测试显示出更好的I型错误控制.
- 推的统计推断将CMAE或UMVCUE与中期p测试相结合,以提高准确性和效率.
相关概念视频
01:15Assumptions of Survival Analysis
83
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
83
01:20Comparing the Survival Analysis of Two or More Groups
115
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
115
01:09Censoring Survival Data
55
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
55
01:24Kaplan-Meier Approach
74
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
74
01:23McNemar's Test
118
McNemar's Test is a nonparametric statistical test used to determine if there is a significant difference in proportions between two related groups when the outcome is binary (e.g., yes/no, success/failure). It is beneficial when we have paired data, such as pre-test/post-test designs, where the same subjects are measured under two different conditions. The test is named after the statistician Quinn McNemar, who introduced it in 1947. It is commonly used in situations where subjects are...
118
01:16Crossover Experiments
2.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.7K